NSEAddendum1 Nov 2026 · 1 Nov 2026, 04:58 pm
Addendum
Sai Parenterals Limited · SAIPARENT
✦ AI SummaryResults
Sai Parenterals Limited has informed the Exchange about the outcome of its Board Meeting held on November 1, 2026. The meeting considered and approved the un-audited financial results for the quarter and half year ended September 30, 2026, and the acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary of the Company.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sai Parenterals Limited has informed the Exchange about Addendum
Attachments (1)
📄pdf
Download →
SAIPARENTERALS_01112026165810_OUTCOMESigned.pdf
View document text
SATI
PARENTERALS
Date: 01° November, 2026
The Manager The Manager
BSE Limited NSE Limited
P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex,
Mumbai-400001 Bandra (E), Mumbai- 400051.
(BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT)
Unit: Sai Parenteral’s Limited
Sub: Outcome of Board Meeting held on Sunday, 01t November, 2026.
With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of
Sai Parenteral’s Limited held on Sunday, the 01* day of November, 2026 at 12:30 p.m. at the
Registered Office of the Company considered and approved the following:
1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year
ended September 30, 2026.
2. Limited Review Reports (Standalone and Consolidated) for the quarter and half year ended
September 30, 2026.
3. Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private
Limited, a subsidiary of the Company in which the company holds 75%, thereby making it
a wholly owned subsidiary of the Company. (Details are attached as Annexure A)
4. Constitution of Management Committee for smooth functioning and administration
convenience of the Company. (Details are attached as Annexure B)
5. Pursuant to the approval of the Board of Directors of the Company at its meeting held on
August 11, 2026, the Company has completed the acquisition of 60% of the equity share
capital of Saicriti Pharma Private Limited. Consequent to the aforesaid acquisition, Saicriti
Pharma Private Limited has become a subsidiary of the Company with effect from the date
of completion of the acquisition.
SAIPARENTERALS
www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032.
frvrmmemmesepsemt mail: infoasaiparontorals.co©m 1917997991306
Email: infoasai toral +
SATI
PARENTERALS
The Meeting concluded at 2:30 p.m.
This is for the information and records oft he Exchanges, please.
Thanking you.
Yours sincerely,
For Sai Parenterals Limited
Anil Kumar Karusala
Managing Director
(DIN- 01866646)
SAIPARENTERALS
www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032.
frvrmmemmespey mail: infoasaiparontorals.co©m 1917997991306
Email: infoasai toral +
SATI
PARENTERALS
Annexure— A
Re: 'ments) Regulations, 2015 read
CFD-POD2/1/3762/2026 dated January
Name of the Target | M/s. SP Analytics Private Limited
Entity
Details in brief such | Nil
as size, turnover etc
Whether the | The acquisition falls within the ambit of Related Party Transactions (RPTs)
acquisition would | under the applicable provisions of the Companies Act, 2013 and SEBI
fall within related | (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the
party transaction(s) | entity being acquired is a related party of the Company. Further, the
and whether the | Promoter(s)/Promoter Group have an interest in the entity being acquired by
promoter/promoter | virtue of their relationship with the said entity.
group/ group
companies have any | The transaction is proposed to be undertaken at arm’s length, based on the
interest in the entity | terms and conditions mutually agreed upon by the parties and duly supported
being acquired? If | by an appropriate assessment, wherever applicable.
yes, nature of
interest and details
thereof and whether
the same is done at
“arm’s length”
Industry to which | Pharma Sector
the entity being
acquired belongs
Objects and impact | Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics
of acquisition | Private Limited, a subsidiary of the Company in which the company holds
(including but not | 75%, thereby making it a wholly owned subsidiary of the Company.
limited to,
disclosure of
reasons for
acquisition of target
entity, if its business
is outside the main
line of business of
the listed entity)
Brief Details of any | Not required
governmental or
regulatory
approvals required
for the acquisition
Indicative Time | On or before 31.12.2026
period for
completion of the
acquisition
SAI PARENTERALS
www.saiparenterals.com Registered office = Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032
frvrmmemmesepsemt mail: infoasaiparontorals.co©m 1917997991306
Email: infoasai toral +
SATI
PARENTERALS
Consideration - Cash
whether cash
consideration or
share swap or any
other form and
details of the same
Cost of acquisition Acquisition of 2,500 equity shares of face value Rs.10/- each, aggregating to
and/or the price at Rs.25,000/-.
which the shares are
acquired
Percentage of Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics
shareholding / Private Limited, a subsidiary of the Company in which the company holds
control acquired 75%, thereby making it a wholly owned subsidiary of the Company.
and / or number of
shares acquired
Brief background M/s. S P Analytics Private Limited was incorporated on November 16, 2023,
about the entity with the main object of undertaking testing, analysis and examination of
acquired in terms of pharmaceuticals, medicines, drugs and other related materials. The Company
products/line of has reported nil turnover during the last three financial years.
business acquired,
date of
incorporation,
history of last 3
years turnover,
country in which the
acquired entity has
presence and any
other significant
information (in
brief);
SAIPARENTERALS
wwiw.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032.
Email: infoasaiparontorals.com (© 1917997991306
CIN:U24231762001PLCO36043
SATI
PARENTERALS
Annexure— B
MANAGEMENT COMMITTEE
S.No | Name Designation Category
1. Anil Kumar Karusala Managing Director Chairman
2. Vijitha Gorrepati Whole Time Director | Member
3. Kunal Kakumanu Executive Director Member
4. Arvind Gannimitta Chief Operating Officer | Member
5. Ashwani Singh Bisht Company Secretary & | Member
Compliance Officer
SAIPARENTERALS
www.saiparenterals.com Registered office : Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad -500032.
frvrmmemmespey mail: infoasaiparontorals.co©m 1917997991306
Email: infoasai toral +
SAI PARENTERAL'S LIMITED
Regd. Off.; Plot No 39, 5th Floor Lavanya Arcade. Jayabheri Enclave, Gachibowii, Seri Lingampally, Telangana, India - 600032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301
Unaudited Consolidated Financial Results For The Quarter And Half Year Ended On 30th September, 2026
(<in Millions)
warter Ended Half Yearndeg inancial Year
3 Particulars ¢ Ended
No. 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026
Unaudited |Unaudited _|Unaudited _[Unaudited | Audited | _Audited
1 |income
2. Revenue from Operations 194018| 178672 53528 373590 86918 | 3,80998
b. Other income 3719 3741 1335 7460 25.09 85.20
Total income 198637 182013 54863 | 3,81050] 894.27]| 38918
W [Expenses
2. Cost of materials consumed 82244 | 116123 20038 | 19m366| es226| 238112
b. Purchases of stock in trade -
<. Change in inventories of finished goods, workn-progress and stoc) 207.63 (98.97) (52:86) 10866 (86.12) an
d. Employees benefits expense 12855 15.42 399 24397 6853 29281
e. Finance costs 8982 93.60 2167 183.42 4631 184.38
. Depreciation and amartisation expense 25090 8110 14.36 33200 2885 16852
/& Other Expenses 38814 37386 3755 762.00 7285 707.96
Total Expenses 188708 172623 a57.09 | 3,61371| 78268 3,750
10 {Profit/(Loss) before Exceptional Items & Tax (1) 9889 97.90 o154 19%.79 mss| 1928
IV |Exceptional Items (Refer Note No.3) -
vV [Profit/{Loss) before Tax (1) 98.89 9750 91.54 19679 11159 11928
VI [Tax expense:
Current tax 1615 an 2804 5786 3154 4934
Deferred tax (22.36) (23.05) (#s.41) 240 (72565)
Earlier Years - - -
Vil Profit/{Loss) after tax 105,10 79.3 63.50 18433 7764 102,59
|Share in Profit/(Loss) after tax in Associate Company
[Showing first 8,000 characters — download PDF for full document]